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Background: The surgical resection of lung disrupts glucose homeostasis and causes hyperglycemia, as in any
other major surgery or critical illness. We performed a prospective study where we carefully lowered hyperglycemia
by insulin administration during the surgery, and for the first time we monitored immediate insulin effects on lung
physiology and gene transcription.
Methods: The levels of blood gases (pH, pCO2, pO2, HCO3-, HCO3- std, base excess, FiO2, and pO2/FiO2) were
measured at the beginning of surgery, at the end of surgery, and two hours after. Samples of healthy lung tissue
surrounding the tumour were obtained during the surgery, anonymized and sent for subsequent blinded qPCR
analysis (mRNA levels of surfactant proteins A1, A2, B, C and D were measured). This study was done on a cohort
of 64 patients who underwent lung resection. Patients were randomly divided, and half of them received insulin
treatment during the surgery.
Results: We demonstrated for the first time that insulin administered intravenously during lung resection does
not affect levels of blood gases. Furthermore, it does not induce immediate changes in the expression of surfactant
proteins.
Conclusion: According to our observations, short insulin treatment applied intravenously during resection does not
affect the quality of breathing.Background
Stress accompanying a major surgery or critical illness
disrupts glucose homeostasis. This disruption leads to
hyperglycemia which is associated with a higher mortal-
ity rate of patients with severe illness [1]. Patients may
also suffer from hyperglycemia during lung resection [2].
The protocol of decreasing stress-induced hyperglycemia
involves insulin; however, the effect of insulin therapy on
lung tissue is not clearly understood. To unravel mech-
anism of insulin action, we mapped gene transcription
affecting lung surfactant production in resected lung
tissue.
In our previous study, we focused on the effects of
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unless otherwise stated.cell lines. However, the results obtained from different cell
lines differed significantly. Therefore, we designed and
tested a way of studying insulin effects on gene transcrip-
tion in patient lungs [3]. This study includes performing
the same experiment on a larger cohort of patients. How-
ever, this time, we did not analyze only gene transcription
but also changes in lung physiology accompanying insulin
administration were closely observed. Our goal was to
clarify whether or not short-term intravenous insulin
therapy affects lung function. For our purposes, the pa-
rameters of acid-base balance obtained from arterial
blood were selected as markers of lung function, and
the composition of lung surfactant was also assessed
through the transcription levels of lung surfactant-
associated genes [4-6].
Lung surfactant is a mixture of phospholipids and pro-
teins. Its primary role is to lower surface tension, which
prevents the alveoli from collapsing. Its secondary role istd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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teins bind to pathogens and stimulate their phagocytosis
and lysis. Four proteins are associated with lung surfac-
tant [7]. Although these proteins only comprise approxi-
mately 10% of the surfactant mass, they are essential for
its function [8]. The levels of proteins associated with
lung surfactant and levels of their RNA were studied
together with levels of blood gases in order to describe
the effects of intravenously supplied insulin during lung
resection.
While performing insulin therapy, it is crucial to pre-
vent hypoglycemia. Studies on intensive insulin therapy
point out the danger of hypoglycemia that occurs in up
to 5% of patients and poses a severe complication. Due to
this possible threat, the benefits of insulin therapy have
been questioned [9]. Hypoglycemia was found to be
connected to the time patients spend on the protocol
(the longer the therapy, the higher the chance of hy-
poglycemia) making the strict monitoring of glucose
levels even more important during intensive insulin
therapy [10-12]. The latest results show that maintain-
ing glucose levels at 7.8-10.0 mmol/l rather than 4.4 to
6.1 mmol/l decreases the number of hypoglycemic pa-
tients while preserving the beneficial effects of insulin
therapy [13,14]. In our study, the risk of hypoglycemia
was lower because we utilized short insulin therapy.
Nevertheless, blood glucose levels were strictly observed
in order to protect patients’ health while monitoring the
effects of insulin therapy during lung resection. The
benefits of insulin therapy in surgical intensive care
units have also been described [15].
Methods
Patients
This study was performed on a cohort of 64 patients
(Table 1). The patients were suffering from lung adeno-
carcinoma (28), squamous cell carcinoma (12), large cell
carcinoma (4), other tumors (10), metastasis (5), or non-Table 1 Basic characteristics of the total patient cohort
Total
Insulin treated N % N
Yes 31 48.4 31
No 33 51.6 -
Age
Mean (SD) Median (Min-Max) Mean (SD
64.9 (9.5) 66.2 (37.0-80.7) 65.0 (9.5
Sex N % N
Male 37 57.8 17
Female 27 42.2 14
Diabetes N % N
No 49 76.6 20
Yes 15 23.4 11malignant disease (5). The partial pressure of O2 (pO2;
standard 72-100 mmHg) and CO2 (pCO2; standard
35-46 mmHg), the arterial blood pH (standard 7.35-
7.45), HCO3- (standard 21-26 mmol/l), HCO3- std (stand-
ard 23-27 mmol/l), fraction of inspired oxygen (FiO2),
Horowitz index (paO2/FiO2; 350-450 mmHg), and base
excess (BE; standard -2 to +2 mmol/l) were measured in a
blood sample collected anaerobically from peripheral
artery [16-18]. The following types of lung resection were
performed: lobectomy (53), pneumonectomy (2), and
atypical resection (9). Surgery was performed under gen-
eral anesthesia with added epidural anaesthesia or paraver-
tebral block. The lung was ventilated selectively: pressure
operated ventilation with FiO2 0.4-0.7, positive end-ex-
piratory pressure (PEEP) 5 cm, and inspire pressure 12-18
cm above PEEP in such a way that the breath volume was
approximately 6 ml/kg and the pCO2 was expired in a
mixture of 4.0-4.5 kPa. None of the patients experienced
post-operative respiratory insufficiency. The levels of
blood gases were determined in arterial blood obtained
before the beginning of insulin administration (operation),
at the end of the operation, and two hours after the end of
the operation.
The patient cohort was independently randomized
into two groups: with or without insulin administration.
Two subgroups of non-diabetic and diabetic patients
were also distinguished. Insulin (insulinum humanum
rapid) was administered to maintain glycemia at 6.0-8.0
mmol/l during surgery. The blood glucose levels were
evaluated every hour in arterial blood. The average dose
of insulin per patient was 24.15 units. Infusion of 10%
glucose was administered. The speed of infusion was ap-
proximately 50 ml/h, and the glucose uptake was always
maintained at 1 mg/kg/min. At the beginning of the
study, six patients experienced hypoglycemia below 4
mmol/l; therefore, the first dosage of insulin was lowered
from 8 to 6 units/h for patients who had normoglycemia
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6.4 mmol/l range, but above 6.0 mmol/l [9,19]. We kept
it within the range of 6.0-8.0 mmol/l.
Samples from 46 patients were anonymized and ana-
lyzed by qPCR (Table 2); the other 18 samples had to be
excluded from the qPCR analysis because of low RNA
quality. A written informed consent form for the scien-
tific use of biological material was signed by all the
patients in accordance with the requirements of the St.
Anne’s University Hospital Ethical Committee before the
samples were included in the study.RNA isolation
After removal, samples of healthy lung tissue surrounding
the tumor were immediately stored in RNAlater (Ambion,
Austin, TX, USA) solution according to the manufac-
turer’s instructions until RNA was isolated. The samples
were homogenized with a MagNA Lyser Instrument
(Roche Diagnostics, Mannheim, Germany) prior to RNA
isolation.
Upon homogenization, total RNA was isolated with
the RNeasy kit (Qiagen, Hilden, Germany) according to
the standard protocol. The RNA concentration was de-
termined spectrophotometrically (NanoDrop ND-1000,
NanoDrop Technologies, Wilmington, DE, USA). RNA
integrity was analyzed with a 2100 Bioanalyser (Agilent
Technologies, Santa Clara, CA, USA). Samples with a
RIN number higher than 5, which indicated good quality
RNA, were used for further analysis [20].Reverse transcription
cDNA was synthesized from 2 μg RNA using Super-
Script II reverse transcriptase (Invitrogen, Carlsbad,
CA, USA) and oligo (dT) primers (Sigma-Aldrich, St.
Louis, MO, USA), according to the manufacturer’s in-
structions. RNasin RNase Inhibitor (Promega, Mannheim,
Germany) was added.Table 2 Basic characteristics of the qPCR patient cohort
Total
Insulin treated N % N
Yes 23 50 23
No 23 50 -
Age
Mean (SD) Median (Min-Max) Mean (SD
65.0 (9.5) 66.2 (37.0-80.3) 64.7 (9.2
Sex N % N
Male 27 58.7 11
Female 19 41.3 12
Diabetes N % N
No 36 78.3 15
Yes 10 21.7 8qPCR
The TaqMan® Gene Expression Master Mix was used
together with the TaqMan® Gene Expression Assays
SFTPA1: Hs01921510_s1, SFTPA2: Hs00359837_m1,
SFTPB: Hs00167036_m1, SFTPC: Hs00161628_m1, and
SFTPD: Hs00358340_m1 (Applied Biosystems, Foster
City, CA, USA). 100 ng of cDNA and Human GAPDH
Endogenous Control (Applied Biosystems, Foster City,
CA, USA) were added to each reaction. The choice of
GAPDH as a reference gene was based on GAPDH
having a stringent correlation in the lung cells and the
least variation of the seven common reference genes [21].
The PCR was performed in a 96-well plates format (25 μl
per well) on a 7500 Real-Time PCR System (Applied
Biosystems, Foster City, CA, USA). The temperature
settings were as follows: step 1 at 50°C for 2 minutes, step
2 at 95°C for 10 minutes, step 3 at 95°C for 15 seconds,
and step 4 at 60°C for 1 minute. Steps 3 and 4 were re-
peated 40×. The expression data were calculated using the
comparative ΔCt method as described elsewhere [22].
Only normalization to the housekeeping gene (GAPDH)
was used.
Statistical analysis
Basic descriptions of the patients and variables were
performed using frequency tables and the following de-
scriptive statistics: mean, standard deviation, median,
minimum and maximum. To evaluate the difference in
values between the initial examination and subsequent
examinations, a paired t-test was used. For evaluating
the difference in values between two independent groups
of patients, a standard two-sample t-test was applied.
The normal distribution of values was verified gra-
phically. For a non-normal distribution of values, the
Wilcoxon test was used for paired data; for comparing
two groups of patients, the Mann-Whitney test was
used. The relationship between two continuous variables
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http://www.biomedcentral.com/1471-2466/14/155the presence of outliers in the use of insulin). For qPCR
experiments, the results were assessed with a two-way
ANOVA with insulin administration as an explanatory
variable. The standard level for statistical significance,
α = 0.05, was used.
Results
Effects of insulin on lung physiology
To define the effects of the surgery and insulin, blood
gas levels were measured at the initial examination, at
the end of the surgery, and two hours after the surgery.
The change was calculated as a difference between
the final and first variable. Negative values represent
a decrease in the selected variable during the surgery
(Table 3).
Statistically significant decreases were found between
the initial examination and the examination at the end
of the surgery in pH, HCO3-, HCO3- std, and BE within
the entire group and within the control group. Within
the insulin-treated group, only small decreases wereTable 3 Changes between the initial examination and the exa



























Bold numbers indicate P value<0.05.detected in HCO3- std and BE (Table 3). When the en-
tire insulin-treated group was compared with the entire
control group, we found a statistically significant decrease
in HCO3- (p = 0.046) between the initial examination and
the examination at the end of the surgery (Table 3
describes only changes within each group), whilst the
other variables remained unchanged.
Similarly, statistically significant decreases were found
between the initial examination and the examination 2
hours after surgery in pH, pO2, pCO2, HCO3-, HCO3-
std, and BE within the entire group and the control
group. Within the insulin-treated group, decreases in
pO2, pCO2, HCO3-, HCO3- std, and BE were detected
(Table 4). When the insulin-treated group was compared
with the control group, we found that there is no sta-
tistically significant change in the observed variables
between the initial examination and the examination
2 hours after surgery.
Table 5 summarizes the changes observed between the
initial examination and the examination at the end ofmination at the end of the surgery
Median change Min Max p
-0.03 -0.16 0.19 0.001
0.10 -5.10 2.20 0.359
-1.60 -36.10 26.60 0.173
-0.55 -4.10 6.10 0.012
-0.65 -4.30 2.20 <0.001
-0.90 -5.80 1.60 <0.001
0.00 -0.60 0.50 0.461
-25.35 -268.50 366.00 0.570
Median change Min Max p
-0.02 -0.15 0.09 0.069
0.10 -1.20 2.20 0.675
-2.10 -25.80 12.50 0.158
-0.30 -4.10 6.10 0.719
-0.30 -3.60 2.20 0.044
-0.50 -4.60 1.60 0.008
0.00 -0.40 0.50 0.937
-30.00 -204.00 162.75 0.242
Median change Min Max p
-0.04 -0.16 0.19 0.005
0.40 -5.10 2.00 0.420
-1.40 -36.10 26.60 0.469
-1.10 -4.10 2.10 0.001
-1.50 -4.30 2.20 <0.001
-1.70 -5.80 1.30 <0.001
0.00 -0.60 0.40 0.362
0 -268.50 366.00 0.922
Table 4 Changes between the initial examination and the examination 2 hours after the surgery
All patients N = 64 Mean change SD Median change Min Max p
pH 0.02 0.07 0.02 -0.13 0.19 0.019
pCO2 -0.84 1.00 -0.85 -4.00 1.30 <0.001
pO2 -12.02 10.79 -11.05 -48.80 15.40 <0.001
HCO3- -2.00 2.36 -2.25 -7.80 7.00 <0.001
HCO3- std -1.15 1.98 -1.05 -6.30 2.60 <0.001
BE -1.48 2.36 -1.55 -7.70 5.90 <0.001
Insulin treated N = 31 Mean change SD Median change Min Max p
pH 0.03 0.06 0.03 -0.10 0.17 0.008
pCO2 -0.80 0.76 -0.80 -2.40 0.80 <0.001
pO2 -12.52 9.53 -9.70 -37.20 3.50 <0.001
HCO3- -1.59 1.98 -1.70 -5.30 2.50 <0.001
HCO3- std -0.77 1.73 -0.90 -4.40 2.10 0.019
BE -1.11 1.92 -1.40 -5.90 2.90 0.003
Control N = 33 Mean change SD Median change Min Max p
pH 0.01 0.08 0.00 -0.13 0.19 0.377
pCO2 -0.87 1.20 -1.00 -4.00 1.30 <0.001
pO2 -11.55 11.98 -11.30 -48.80 15.40 <0.001
HCO3- -2.38 2.64 -2.70 -7.80 7.00 <0.001
HCO3- std -1.50 2.16 -1.50 -6.30 2.60 <0.001
BE -1.83 2.69 -1.80 -7.70 5.90 <0.001
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diabetes. No significant differences were observed be-
tween the diabetes and non-diabetes group. However,
significant differences were observed between the initial
examination and the examination 2 hours after the sur-
gery in insulin-treated patients with or without diabetes
(Table 6). Statistically significant decreases in all of the
measured variables were found for non-diabetic patients.
In the diabetic group, almost the same changes (increase
in pH, decrease in all of the other variables) were mea-
sured, but the results were not statistically significant.
This lack of significance might be due to the smaller size
of the diabetes group. These results are in agreement
with the results of the entire insulin-treated group.
Post-operative respiratory insufficiency was not reported
in any patient regardless of insulin administration. During
hospitalization, typically lasting 6 to 10 days, no organ fail-
ure was reported.
Effects of insulin on gene transcription
The effect of insulin was also studied on anonymized
samples from healthy lung tissue surrounding the tumor
obtained from patients during lung resection (Table 7). To
obtain valid results, only samples with high-quality RNA
were included in the qPCR analysis of lung surfactant-
associated genes. Therefore, the effects of insulin on gene
expression were studied in only 46 out of the 64 patients.We demonstrated that expression levels of SFTPA1,
SFTPA2, SFTPB, SFTPC, and SFTPD remain unchanged
with respect to insulin treatment (Figure 1). Even though
a distinct change was found in SFTPA2 expression level
upon insulin treatment, it was not statistically significant
(p = 0.095) (Figure 1).
Discussion
Our goal was to examine whether insulin affects the
quality of breathing via affecting lung physiology and
gene transcription. For our purposes, lung physiology
was defined as blood gas levels and the genes of interest
were the genes of surfactant proteins. The issue of insu-
lin therapy and lowering hyperglycemia has been greatly
discussed but to the best of our knowledge, there is no
previous study focused on the immediate effects of insu-
lin on lung physiology and the transcription of surfac-
tant proteins performed on actual patients.
Effects of insulin on lung physiology
Initially, we focused on the differences in blood gas
levels among different groups of patients at different
points in time (initial examination, end of the surgery,
and 2 hours after the surgery). The comparison of the
insulin-treated group and the control group showed that
the only statistically significant difference was a decrease
in HCO3- (p = 0.046) between the initial examination and
Table 5 Changes between the initial examination and the examination at the end of the surgery in insulin-treated
diabetic and non-diabetic patients
Insulin treated N = 31 Mean change SD Median change Min Max p
pH -0.02 0.06 -0.02 -0.15 0.09 0.069
pCO2 0.06 0.81 0.10 -1.20 2.20 0.675
pO2 -2.01 7.72 -2.10 -25.80 12.50 0.158
HCO3- -0.12 1.83 -0.30 -4.10 6.10 0.719
HCO3- std -0.53 1.39 -0.30 -3.60 2.20 0.044
BE -0.77 1.52 -0.50 -4.60 1.60 0.008
FiO2 0.00 0.18 0.00 -0.40 0.50 0.937
pO2/FiO2 -21.38 99.68 -30.00 -204.00 162.75 0.242
Non-diabetes N = 20 Mean change SD Median change Min Max p
pH -0.01 0.05 -0.01 -0.14 0.09 0.269
pCO2 0.01 0.76 -0.10 -1.20 1.60 0.930
pO2 -1.04 5.98 -1.40 -10.90 12.50 0.448
HCO3- -0.22 1.89 -0.40 -4.10 6.10 0.617
HCO3- std -0.47 1.37 -0.30 -3.60 1.90 0.141
BE -0.69 1.56 -0.40 -4.60 1.60 0.062
FiO2 -0.01 0.14 0.00 -0.40 0.15 0.655
pO2/FiO2 -12.98 84.60 -25.35 -184.58 162.75 0.500
Diabetes N = 11 Mean change SD Median change Min Max P
pH -0.03 0.07 -0.02 -0.15 0.08 0.162
pCO2 0.15 0.93 0.20 -1.00 2.20 0.614
pO2 -3.78 10.27 -3.70 -25.80 8.40 0.250
HCO3- 0.05 1.80 0.10 -3.20 2.80 0.922
HCO3- std -0.63 1.49 -0.80 -2.50 2.20 0.193
BE -0.92 1.50 -0.50 -3.40 1.30 0.070
FiO2 0.02 0.25 0.00 -0.40 0.50 0.811
pO2/FiO2 -36.53 125.63 -63.75 -204.00 148.73 0.357
Bold numbers indicate P value <0.05.
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t-test (p = 0.05) demonstrated no significant effect of
insulin on oxygenation during lung resection (Table 3).
When the group of insulin-treated patients was divided
into non-diabetic and diabetic patients (Tables 5 and 6),
the analysis showed no difference between these groups.
However, it is important to keep in mind that the diabetes
group was small; therefore, the statements based on the
result of the diabetes group should not be overestimated.
If we focus on the changes within the selected groups
(as shown in Tables 3, 4, 5 and 6) between the initial
measurement and the end of surgery or two hours after
surgery, we found the following: the results from the acid-
base balance measurements represent almost typical data
within the reference limits of all of the measured variables
[23]. The mean data from the initial examination and the
examination at the end of the surgery show low compen-
sated respiratory acidosis in both groups – the controland the insulin-treated group [24]. This result seems to be
partly caused by metabolic acidosis.
The evaluation of the differences between the initial
examination, the examination at the end of the surgery,
and the examination two hours after the surgery con-
firms a slight acidifying effect after the surgery (HCO3-,
BE, and pH decreased, Tables 3 and 4). This effect was
still present two hours after the surgery and it was most
likely induced by stress caused by the surgery. Acidosis
in the insulin-treated group was lower than the control
group, but the difference was minimal and was most
likely caused by the catabolic effect of insulin [25,26].
Considering the partial pressure of oxygen, it must be
noted that change of its value before and after surgery
may be explained by many other conditions, for example:
persisting anesthesia, atelectasis, bronchospasm, the extent
of surgery, pain, and analgesia. Changes in the Horowitz
Index (paO2/FiO2) were not significant.
Table 6 Changes between the initial examination and the examination 2 hours after the surgery in insulin-treated
diabetic and non-diabetic patients
Insulin treated N = 31 Mean change SD Median change Min Max P
pH 0.03 0.06 0.03 -0.10 0.17 0.008
pCO2 -0.80 0.76 -0.80 -2.40 0.80 <0.001
pO2 -12.52 9.53 -9.70 -37.20 3.50 <0.001
HCO3- -1.59 1.98 -1.70 -5.30 2.50 <0.001
HCO3- std -0.77 1.73 -0.90 -4.40 2.10 0.019
BE -1.11 1.92 -1.40 -5.90 2.90 0.003
Non-diabetes N = 20 Mean change SD Median change Min Max p
pH 0.03 0.06 0.03 -0.10 0.13 0.030
pCO2 -0.90 0.70 -0.95 -2.10 0.10 <0.001
pO2 -12.64 7.92 -11.75 -29.20 2.80 <0.001
HCO3- -1.77 2.05 -2.00 -4.70 2.50 0.001
HCO3- std -0.92 1.70 -1.05 -4.40 2.10 0.026
BE -1.36 2.04 -1.30 -5.90 2.90 0.008
Diabetes N = 11 Mean change SD Median change Min Max p
pH 0.03 0.07 0.02 -0.07 0.17 0.148
pCO2 -0.63 0.86 -0.70 -2.40 0.80 0.036
pO2 -12.30 12.37 -9.10 -37.20 3.50 0.008
HCO3- -1.25 1.90 -1.20 -5.30 0.90 0.054
HCO3- std -0.51 1.83 -0.70 -4.10 1.80 0.379
BE -0.66 1.67 -1.40 -3.40 2.00 0.218
Bold numbers indicate P value <0.05.
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periment. As expected, our measurements revealed a
significant difference in glycemia among the patients
who were given insulin and those who were not (p = 0.002;
data not shown). In the control group, the level of glycemia
was increased. An increasing level of glycemia indicates the
typical pathophysiological reaction to stress induced by
surgery. This reaction was prevented by insulin administra-
tion. Unfortunately, there was a relatively high occurrence
of hypoglycemia among the patients despite strict insulin
regulation and the relatively short duration of the expe-
riment (compared to intensive insulin therapy). In the
insulin-treated group, there were 7 cases of hypoglycemia
lower than 4 mmol/l and 1 case occurred in the control
group. This result excludes the possibility that the lack ofTable 7 Summary of selected gene expression levels accordin
Gene
Insulin treated (N = 23)
Mean SD Median Min Max
SFTPA1 5.44 3.04 5.40 0.75 13.13
SFTPA2 12.00 11.54 8.69 1.47 46.53
SFTPB 5.83 3.46 4.90 1.77 15.63
SFTPC 59.95 33.14 58.22 12.55 138.14
SFTPD 0.49 0.22 0.42 0.14 1.04an effect of insulin on oxygenation could have been caused
by an insufficient dosage of insulin during the experiments.
In summary, the statistically significantly lower level of
acidosis in the insulin-treated group has no clinical value
in the cohorts of patients included in this study. We de-
monstrated that intravenously supplied insulin during
lung resection does not improve oxygenation.
Effects of insulin on gene transcription
Based on our previous experiments on lung cancer cell
lines [3] and other studies [5,6], we anticipated that insu-
lin therapy would regulate the expression of pulmonary
surfactant-associated genes. However, qPCR analyses of
lung tissue samples demonstrated that there are no sta-
tistically significant insulin-induced changes in the geneg to insulin administration
Control (N = 23)
p
Mean SD Median Min Max
4.59 3.73 2.95 0.54 15.24 0.130
6.47 3.87 5.06 1.95 13.64 0.095
5.81 3.99 4.27 1.02 15.08 0.663
54.51 51.26 34.22 2.70 190.68 0.238
0.45 0.22 0.40 0.15 0.91 0.601
Figure 1 Graph of selected gene expression levels normalised to GAPDH with and without insulin treatment.
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and SFTPD upon insulin treatment. The level of SFTPA2
seems to double after insulin treatment, however the
change was not statistically significant (p = 0.095). The
probability that longer treatment or a higher dose of insu-
lin could result in a significant change is low because
results from other experiments suggest the opposite. In-
sulin is suspected to inhibit the transcription of SFTPA
through the PI 3-kinase signaling pathway [6].
In human fetal lung explants maintained in vitro
for 6 days, insulin was found to down-regulate SFTPA
(isoforms were not distinguished) and SFTPB while not
affecting SFTPC [4]. The isoforms of SFTPA not being
distinguished in that study makes the comparison even
more difficult.
In another study, the authors described the inhibitory
effects of insulin on SFTPA (again the two isoforms were
not distinguished) and SFTPB in the H441 cell line. The
H441 cell line is used as a model of the Clara cells, lung
surfactant-producing cells located in the bronchi. For
SFTPA, a decrease was observed after only 4 hours of
treatment, but it was 24 hours before an inhibitory effect
was observed on SFTPB [27]. In our experiments, sam-
ple removal usually occurred 4 to 5 hours after the first
administration of insulin to the patient. The effects of
insulin were studied in another study using human fetal
lung explants and H441 cells [5]. Insulin was found to
down-regulate both SFTPA1 and SFTPA2 in fetal lung
explants (cell culture was exposed to 2500 ng/ml insulin
for 6 days) and SFTPA1 only in H441 cells (cell culture
was exposed to 2500 ng/ml insulin for 24 hours).
Furthermore, in our own previously published experi-
ments, the inhibitory effects of insulin on the transcription
of the SFTPB, SFTPC and SFTPD genes in H441 cells and
the SFTPB gene in A549 cells were observed [3].
In the situation in which insulin affects lung surfactant-
associated genes differently in different models, we presentresults obtained from actual patients. The experiments
performed with the cell lines may not accurately reflect
the in vivo situation. Also, large changes in surfactant
production and composition that occur in fetal lungs [28]
cannot be reliably applied to mature lungs. We cannot
exclude the possible effects of insulin on lung surfactant-
associated gene expression after a longer period of time.
However, insulin administration could not be prolonged
in our experiments because maintaining stable condition
of the patients was the priority. Administering insulin after
the surgery would increase the risk of hypoglycemia and
taking more lung samples after the surgery would be un-
acceptable.Conclusions
We demonstrated for the first time that insulin-induced
changes in levels of blood gases and the parameters of
acid-base balance obtained from arterial blood were
minimal, and their physiological impact on patients was
negligible.
Furthermore, gene expression analysis revealed no im-
mediate changes induced by short-time insulin treat-
ment in SFTPA1, SFTPA2, SFTPB, SFTPC, or SFTPD.
Therefore, we conclude that according to our observa-
tions, intravenously supplied insulin during lung resec-
tion does not affect the quality of breathing. The other
potential effects of insulin therapy and controlling
glycemia were not the focus of this study. Based on
the occurrence of hypoglycemia in our study, we also
recommend maintaining glycemia levels within 6.0-8.0
mmol/l or within 7.8-10.0 mmol/l instead of the 4.6-
6.4 mmol/l range. The first dose of insulin should not ex-
ceed 6 units of insulin per hour.
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